Doxorubicin is a classical but useful anti-tumour agent. It is used for the treatment of a variety of malignancies including solid tumours and leukaemia due to its broad spectrum anti-tumour activity. It also has well known toxic side effects that must be minimised for its successful use clinically. This book discusses intraperitoneal doxorubicin; preclinical characterisation of the drug-delivery device DCBeads for transarterial chemoembolisation of doxorubicin and nemorubicin; doxorubicin-induced cardiomyopathy; advanced therapies of doxorubicin by carrier of drug delivery system or combined food components; and prevention and management of cariotoxicity.
Preface; Intraperitoneal Doxorubicin:: Rationale, Pharmacokinetic Studies, & Clinical Results; Preclinical Characterization of the Drug-Delivery Device DCBeads for Transarterial Chemoembolization of Doxorubicin & Nemorubicin, a Methoxy-Morpholinyl Derivative; Doxorubicin-Induced Cardiomyopathy; Advanced Therapies of Doxorubicin by Carrier of Drug Delivery System or Combined Food Components; Prevention & Management of Cardiotoxicity, Nausea & Vomiting in Doxorubicin-Treated Breast Cancer Patients; Index.
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.